Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 8/2015

01-08-2015 | Article

Silencing of miR-195 reduces diabetic cardiomyopathy in C57BL/6 mice

Authors: Dong Zheng, Jian Ma, Yong Yu, Minghui Li, Rui Ni, Grace Wang, Ruizhen Chen, Jianmin Li, Guo-Chang Fan, James C. Lacefield, Tianqing Peng

Published in: Diabetologia | Issue 8/2015

Login to get access

Abstract

Aims/hypothesis

MicroRNAs (miRs) have been suggested as potential therapeutic targets for heart diseases. Inhibition of miR-195 prevents apoptosis in cardiomyocytes stimulated with palmitate and transgenic overexpression of miR-195 induces cardiac hypertrophy and heart failure. We investigated whether silencing of miR-195 reduces diabetic cardiomyopathy in a mouse model of streptozotocin (STZ)-induced type 1 diabetes.

Methods

Type 1 diabetes was induced in C57BL/6 mice (male, 2 months old) by injections of STZ.

Results

MiR-195 expression was increased and levels of its target proteins (B cell leukaemia/lymphoma 2 and sirtuin 1) were decreased in STZ-induced type 1 and db/db type 2 diabetic mouse hearts. Systemically delivering an anti-miR-195 construct knocked down miR-195 expression in the heart, reduced caspase-3 activity, decreased oxidative stress, attenuated myocardial hypertrophy and improved myocardial function in STZ-induced mice with a concurrent upregulation of B cell leukaemia/lymphoma 2 and sirtuin 1. Diabetes reduced myocardial capillary density and decreased maximal coronary blood flow in mice. Knockdown of miR-195 increased myocardial capillary density and improved maximal coronary blood flow in diabetic mice. Upregulation of miR-195 sufficiently induced apoptosis in cardiomyocytes and attenuated the angiogenesis of cardiac endothelial cells in vitro. Furthermore, inhibition of miR-195 prevented apoptosis in cardiac endothelial cells in response to NEFA, an important feature of diabetes.

Conclusions/interpretation

Therapeutic silencing of miR-195 reduces myocardial hypertrophy and improves coronary blood flow and myocardial function in diabetes, at least in part by reducing oxidative damage, inhibiting apoptosis and promoting angiogenesis. Thus, miR-195 may represent an alternative therapeutic target for diabetic heart diseases.
Appendix
Available only for authorised users
Literature
1.
International Diabetes Federation (2009) IDF diabetes atlas. International Diabetes Federation, Brussels
2.
Mazzone T, Chait A, Plutzky J (2008) Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet 371:1800–1809PubMedCentralPubMedCrossRef
3.
4.
Meister G, Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431:343–349PubMedCrossRef
5.
Brennecke J, Hipfner DR, Stark A, Russell RB, Cohen SM (2003) Bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell 113:25–36PubMedCrossRef
6.
Xu P, Vernooy SY, Guo M, Hay BA (2003) The Drosophila microRNA Mir-14 suppresses cell death and is required for normal fat metabolism. Curr Biol 13:790–795PubMedCrossRef
7.
8.
9.
Gupta A, Gartner JJ, Sethupathy P, Hatzigeorgiou AG, Fraser NW (2006) Anti-apoptotic function of a microRNA encoded by the HSV-1 latency-associated transcript. Nature 442:82–85PubMed
10.
Fiedler J, Jazbutyte V, Kirchmaier BC et al (2011) MicroRNA-24 regulates vascularity after myocardial infarction. Circulation 124:720–730PubMedCrossRef
11.
Lagendijk AK, Goumans MJ, Burkhard SB, Bakkers J (2011) MicroRNA-23 restricts cardiac valve formation by inhibiting Has2 and extracellular hyaluronic acid production. Circ Res 109:649–657PubMedCrossRef
12.
13.
Boon RA, Iekushi K, Lechner S et al (2013) MicroRNA-34a regulates cardiac ageing and function. Nature 495:107–110PubMedCrossRef
14.
Chen J, Huang ZP, Seok HY et al (2013) mir-17-92 cluster is required for and sufficient to induce cardiomyocyte proliferation in postnatal and adult hearts. Circ Res 112:1557–1566PubMedCentralPubMedCrossRef
15.
16.
Li RC, Tao J, Guo YB et al (2013) In vivo suppression of microRNA-24 prevents the transition toward decompensated hypertrophy in aortic-constricted mice. Circ Res 112:601–605PubMedCentralPubMedCrossRef
17.
18.
19.
van Rooij E, Sutherland LB, Liu N et al (2006) A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A 103:18255–18260PubMedCentralPubMedCrossRef
20.
21.
Zhu H, Yang Y, Wang Y, Li J, Schiller PW, Peng T (2011) MicroRNA-195 promotes palmitate-induced apoptosis in cardiomyocytes by down-regulating Sirt1. Cardiovasc Res 92:75–84PubMedCrossRef
22.
Zhang Y, Peng T, Zhu H et al (2010) Prevention of hyperglycemia-induced myocardial apoptosis by gene silencing of Toll-like receptor-4. J Transl Med 8:133PubMedCentralPubMed
23.
Foster FS, Mehi J, Lukacs M et al (2009) A new 15-50 MHz array-based micro-ultrasound scanner for preclinical imaging. Ultrasound Med Biol 35:1700–1708PubMedCrossRef
24.
Ma J, Wei M, Wang Q et al (2012) Deficiency of Capn4 gene inhibits nuclear factor-kappaB (NF-kappaB) protein signaling/inflammation and reduces remodeling after myocardial infarction. J Biol Chem 287:27480–27489PubMedCentralPubMedCrossRef
25.
Katz PS, Trask AJ, Souza-Smith FM et al (2011) Coronary arterioles in type 2 diabetic (db/db) mice undergo a distinct pattern of remodeling associated with decreased vessel stiffness. Basic Res Cardiol 106:1123–1134PubMedCentralPubMedCrossRef
26.
Li Y, Ma J, Zhu H et al (2011) Targeted inhibition of calpain reduces myocardial hypertrophy and fibrosis in mouse models of type 1 diabetes. Diabetes 60:2985–2994PubMedCentralPubMedCrossRef
27.
Li J, Zhu H, Shen E, Wan L, Arnold JM, Peng T (2010) Deficiency of rac1 blocks NADPH oxidase activation, inhibits endoplasmic reticulum stress, and reduces myocardial remodeling in a mouse model of type 1 diabetes. Diabetes 59:2033–2042PubMedCentralPubMedCrossRef
28.
29.
Zhou YQ, Foster FS, Parkes R, Adamson SL (2003) Developmental changes in left and right ventricular diastolic filling patterns in mice. Am J Physiol Heart Circ Physiol 285:H1563–H1575PubMedCrossRef
30.
Zampetaki A, Attia R, Mayr U et al (2014) Role of miR-195 in aortic aneurysmal disease. Circ Res 115:857–866PubMedCrossRef
31.
Chen YQ, Wang XX, Yao XM et al (2012) Abated microRNA-195 expression protected mesangial cells from apoptosis in early diabetic renal injury in mice. J Nephrol 25:566–576PubMedCrossRef
32.
Herrera BM, Lockstone HE, Taylor JM et al (2010) Global microRNA expression profiles in insulin target tissues in a spontaneous rat model of type 2 diabetes. Diabetologia 53:1099–1109PubMedCentralPubMedCrossRef
33.
Mortuza R, Feng B, Chakrabarti S (2014) miR-195 regulates SIRT1-mediated changes in diabetic retinopathy. Diabetologia 57:1037–1046PubMedCrossRef
34.
Liu L, Chen L, Xu Y, Li R, Du X (2010) microRNA-195 promotes apoptosis and suppresses tumorigenicity of human colorectal cancer cells. Biochem Biophys Res Commun 400:236–240PubMedCrossRef
35.
Sulaiman M, Matta MJ, Sunderesan NR, Gupta MP, Periasamy M, Gupta M (2010) Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 298:H833–H843PubMedCentralPubMedCrossRef
36.
Katare R, Caporali A, Zentilin L et al (2011) Intravenous gene therapy with PIM-1 via a cardiotropic viral vector halts the progression of diabetic cardiomyopathy through promotion of prosurvival signaling. Circ Res 108:1238–1251PubMedCrossRef
37.
Zhou F, Yang Y, Xing D (2011) Bcl-2 and Bcl-xL play important roles in the crosstalk between autophagy and apoptosis. FEBS J 278:403–413PubMedCrossRef
38.
Rane S, He M, Sayed D et al (2009) Downregulation of miR-199a derepresses hypoxia-inducible factor-1alpha and Sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes. Circ Res 104:879–886PubMedCentralPubMedCrossRef
39.
40.
Thirunavukkarasu M, Penumathsa SV, Koneru S et al (2007) Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: role of nitric oxide, thioredoxin, and heme oxygenase. Free Radic Biol Med 43:720–729PubMedCentralPubMedCrossRef
41.
Zhang H, Morgan B, Potter BJ et al (2010) Resveratrol improves left ventricular diastolic relaxation in type 2 diabetes by inhibiting oxidative/nitrative stress: in vivo demonstration with magnetic resonance imaging. Am J Physiol Heart Circ Physiol 299:H985–H994PubMedCentralPubMedCrossRef
42.
Cai L, Kang YJ (2001) Oxidative stress and diabetic cardiomyopathy: a brief review. Cardiovasc Toxicol 1:181–193PubMedCrossRef
43.
44.
Yildirim SS, Akman D, Catalucci D, Turan B (2013) Relationship between downregulation of miRNAs and increase of oxidative stress in the development of diabetic cardiac dysfunction: junctin as a target protein of miR-1. Cell Biochem Biophys 67:1397–1408PubMedCrossRef
45.
Wang N, Yang C, Xie F et al (2012) Gadd45alpha: a novel diabetes-associated gene potentially linking diabetic cardiomyopathy and baroreflex dysfunction. PLoS One 7:e49077PubMedCentralPubMedCrossRef
Metadata
Title
Silencing of miR-195 reduces diabetic cardiomyopathy in C57BL/6 mice
Authors
Dong Zheng
Jian Ma
Yong Yu
Minghui Li
Rui Ni
Grace Wang
Ruizhen Chen
Jianmin Li
Guo-Chang Fan
James C. Lacefield
Tianqing Peng
Publication date
01-08-2015
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 8/2015
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-015-3622-8

Other articles of this Issue 8/2015

Diabetologia 8/2015 Go to the issue

Article

All-cause mortality in a nationwide cohort of childhood-onset diabetes in Norway 1973–2013

Commentary

Hepatokines: unlocking the multi-organ network in metabolic diseases

Article

GIP increases adipose tissue expression and blood levels of MCP-1 in humans and links high energy diets to inflammation: a randomised trial

Letter

Variable effects of statins on glucose homeostasis parameters and their diabetogenic role

Article

Insulin regulates Rab3–Noc2 complex dissociation to promote GLUT4 translocation in rat adipocytes

Commentary

The future of brown adipose tissues in the treatment of type 2 diabetes
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits